Litcius/Paper detail

Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332

Matteo Pavan, Giovanni Bolcato, Davide Bassani, Mattia Sturlese, Stefano Moro

2021Journal of Enzyme Inhibition and Medicinal Chemistry73 citationsDOIOpen Access PDF

Abstract

The chemical structure of PF-07321332, the first orally available Covid-19 clinical candidate, has recently been revealed by Pfizer. No information has been provided about the interaction pattern between PF-07321332 and its biomolecular counterpart, the SARS-CoV-2 main protease (Mpro). In the present work, we exploited Supervised Molecular Dynamics (SuMD) simulations to elucidate the key features that characterise the interaction between this drug candidate and the protease, emphasising similarities and differences with other structurally related inhibitors such as Boceprevir and PF-07304814. The structural insights provided by SuMD will hopefully be able to inspire the rational discovery of other potent and selective protease inhibitors.

Topics & Concepts

ProteaseBoceprevirComputational biologyMechanism (biology)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Mechanism of actionDrug candidateCoronavirus disease 2019 (COVID-19)Protease inhibitor (pharmacology)ChemistryDrug discoveryMolecular dynamicsDrugBiologyBiochemistryEnzymeVirologyPharmacologyMedicineVirusComputational chemistryPhysicsGeneViral loadDiseaseQuantum mechanicsAntiretroviral therapyInfectious disease (medical specialty)GenotypeRibavirinPathologyIn vitroComputational Drug Discovery MethodsSARS-CoV-2 and COVID-19 ResearchProtein Structure and Dynamics
Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332 | Litcius